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Summary
Background Gram-negative Enterobacteriaceae with resistance to carbapenem conferred by New Delhi metallo-β-
lactamase 1 (NDM-1) are potentially a major global health problem. We investigated the prevalence of NDM-1, in 
multidrug-resistant Enterobacteriaceae in India, Pakistan, and the UK.
Methods Enterobacteriaceae isolates were studied from two major centres in India—Chennai (south India), 
Haryana (north India)—and those referred to the UK’s national reference laboratory. Antibiotic susceptibilities 
were assessed, and the presence of the carbapenem resistance gene blaNDM-1 was established by PCR. Isolates were 
typed by pulsed-ﬁ eld gel electrophoresis of XbaI-restricted genomic DNA. Plasmids were analysed by S1 nuclease 
digestion and PCR typing. Case data for UK patients were reviewed for evidence of travel and recent admission to 
hospitals in India or Pakistan.
Findings We identiﬁ ed 44 isolates with NDM-1 in Chennai, 26 in Haryana, 37 in the UK, and 73 in other sites in India 
and Pakistan. NDM-1 was mostly found among Escherichia coli (36) and Klebsiella pneumoniae (111), which were highly 
resistant to all antibiotics except to tigecycline and colistin. K pneumoniae isolates from Haryana were clonal but 
NDM-1 producers from the UK and Chennai were clonally diverse. Most isolates carried the NDM-1 gene on plasmids: 
those from UK and Chennai were readily transferable whereas those from Haryana were not conjugative. Many of the 
UK NDM-1 positive patients had travelled to India or Pakistan within the past year, or had links with these countries.
Interpretation The potential of NDM-1 to be a worldwide public health problem is great, and co-ordinated international 
surveillance is needed. 
Funding European Union, Wellcome Trust, and Wyeth.
Introduction
Bacteria from clinical and non-clinical settings are 
becoming increasingly resistant to conventional antibiotics. 
10 years ago, concern centred on Gram-positive bacteria, 
particularly meticillin-resistant Staphylococcus aureus and 
vancomycin-resistant Enterococcus spp. Now, however, 
clinical microbiologists increasingly agree that multidrug-
resistant Gram-negative bacteria pose the greatest risk to 
public health. Not only is the increase in resistance of 
Gram-negative bacteria faster than in Gram-positive 
bacteria,1,2 but also there are fewer new and developmental 
antibiotics active against Gram-negative bacteria3–6 and 
drug development programmes seem insuﬃ  cient to 
provide therapeutic cover in 10–20 years.7–9
The increase in resistance of Gram-negative bacteria is 
mainly due to mobile genes on plasmids that can readily 
spread through bacterial populations. Standardised 
plasmid typing methods are enhancing our understanding 
of the host ranges of these elements and their worldwide 
distribution.10,11 Moreover, unprecedented human air 
travel and migration allow bacterial plasmids and clones 
to be transported rapidly between countries and 
continents.12,13 Much of this dissemination is undetected, 
with resistant clones carried in the normal human ﬂ ora 
and only becoming evident when they are the source of 
endogenous infections. The CTX-M-15 extended-spectrum 
β-lactamase (ESBL) encoded by blaCTX-M-15 was ﬁ rst reported 
in India in the mid-1990s.14,15 The gene jumped from the 
chromosome of its natural hosts, Kluyvera spp, to 
plasmids that have subsequently spread widely,10,16 
establishing CTX-M-15 as the globally-dominant ESBL 
and the primary cause of acquired resistance to third-
generation cephalosporins in Entero bacteriaceae.17,18 
Recent surveys have identiﬁ ed ESBLs in 70–90% of 
Enterobacteriaceae in India and; although these 
collections might be a biased sample, they do suggest a 
serious problem, making the widespread use of reserved 
antibiotics such as carbapenems necessary.15,19 Rates of 
cephalosporin resistance are lower in other countries but 
the growing prevalence of ESBL producers is suﬃ  cient to 
drive a greater reliance on carbapenems. Consequently, 
there is selection pressure for carbapenem resistance in 
Enterobacteriaceae, and its emergence is a worldwide 
public health concern since there are few antibiotics in 
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reserve beyond carbapenems.20 Already Klebsiella 
pneumoniae clones with KPC carbapenemase are a major 
problem in the USA, Greece, and Israel, and plasmids 
encoding the VIM metallo-carbapenemase have 
disseminated among K pneumoniae in Greece.21
We recently reported a new type of carbapenem 
resistance gene, designated blaNDM-1.22 A patient, repatriated 
to Sweden after admission to hospital in New Delhi, 
India, was colonised by K pneumoniae and Escherichia coli 
with blaNDM-1 on plasmids of varying size, which readily 
transferred between bacterial strains in vitro. We sought 
molecular, biological, and epidemiological data on New 
Delhi metallo-β-lactamase 1 (NDM-1) positive Entero-
bacteriaceae in India and Pakistan and investigated 
importation of the resistance gene into the UK by patients 
returning from the Indian subcontinent.
Methods 
Bacterial isolates 
Isolates of bacteria were identiﬁ ed from Chennai and 
Haryana in India. UK isolates were identiﬁ ed from 
referrals to the Antibiotic Resistance Monitoring and 
Reference Laboratory by UK microbiology laboratories 
between 2003 and 2009. We also identiﬁ ed isolates from 
other sites around Bangladesh, India, and Pakistan.
Procedures
Bacteria were identiﬁ ed via the Phoenix automated 
phenotypic identiﬁ cation criteria (Becton Dickinson, 
Oxford, UK) or with API 20E strips (bioMerieux, 
Basingstoke, UK). Minimum inhibitory concentrations 
(MICs) and carbapenem resistance were established by 
microbroth dilution (Phoenix), British Society for 
Antimicrobial Chemotherapy (BSAC) agar dilution, or 
disc diﬀ usion. 
Modiﬁ ed Hodge (cloverleaf) test involving distorted 
carbapenem inhibition zones and imipenem-EDTA 
synergy tests by disc, or the MBL Etest (AB bioMerieux, 
Solna, Sweden) were used to screen for metallo-β-
lactamase production.23 The presence of blaNDM-1 was 
established by PCR with speciﬁ c primers targeting the 
gene.22 PCR and sequencing were used to identify other 
resistant genes (blaCMY-4 and blaCTX-M-15) carried by the 
bacterial isolates.
Conjugational transfer of antibiotic resistance to the 
laboratory strain E coli J53 was done on blood agar without 
selection. After 18 h, the mixed cultures were washed from 
the plates, suspended in saline, and plated onto MacConkey 
agar containing sodium azide (100 mg/L) and meropenem 
(2 mg/L). Transconjugants were conﬁ rmed to have blaNDM-1 
by PCR analysis. Plasmids were subsequently isolated and 
typed on the basis of their origins of replication, as 
described by Carattoli and colleagues.11
Genomic DNA was prepared in agarose blocks and 
digested with the restriction enzyme XbaI (Roche 
Diagnostics, Mannheim, Germany). DNA fragments were 
separated by pulsed-ﬁ eld gel electrophoresis (PFGE) on a 
CHEF-DR III apparatus (Bio-Rad, Hercules, CA, USA) for 
20 h at 6 V/cm at 14ºC with an initial pulse time of 0·5 s 
and a ﬁ nal pulse time of 30 s. Dendrograms of strain 
relatedness were created with BioNumerics software.
Genomic DNA in agarose blocks was digested with the 
restriction enzyme S1 (Invitrogen, Abingdon, UK). DNA 
fragments were separated by PFGE as above. In-gel 
hybridisation was done with a blaNDM-1 probe labelled with 
³²P (Stratgene, Amsterdam, Netherlands) with a random-
primer method.22 Plasmid DNA bands that hybridised 
with blaNDM-1 were cut from the gel, puriﬁ ed, and typed as 
described by Carattoli and colleauges.11
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
From Chennai, 75 E coli, 60 Klebsiella spp, and six other 
Enterobacteriaceae resistant to carbapenems were 
isolated from 3521 (4%) Enterobacteriaceae analysed 
throughout 2009. Of these 141 carbapenem-resistant 
Enterobacteriaceae, 44 (19 E coli, 14 K pneumoniae, seven 
Enterobacter cloacae, two Proteus spp, one Citrobacter 
freundii, and one Klebsiella oxytoca) were NDM-1 positive 
(about 1% of all resistant isolates). During that same 
period, 47 carbapenem-resistant isolates (24%) of 198 from 
Haryana were identiﬁ ed; from these, 26 (13%) were positive 
for NDM-1, and all were K pneumoniae. The Indian isolates 
from Chennai and Haryana were primarily from 
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Figure 1: Numbers of carbapenemase-producing Enterobacteriaceae referred from UK laboratories to the UK 
Health Protection Agency’s national reference laboratory from 2003 to 2009
The predominant gene is blaNDM-1, which was ﬁ rst identiﬁ ed in 2008. The other group includes diverse producers of 
KPC, OXA-48, IMP, and VIM enzymes. 
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community acquired urinary tract infections, pneumonia, 
and blood-stream infections. The age range was 4–66 years 
with a mean of 36 years (SD 20) and a female to male ratio 
of about two to one. 
In the UK resistant isolates increased in both 2008 and 
2009 (ﬁ gure 1). Isolates with the NDM-1 enzyme, which 
was ﬁ rst detected in the UK in 2008, became the pre-
dominant carbapenemase-producing Entero bacteriaceae 
in 2009, accounting for 32 (44%) of 73 carbapenemase 
producers. During 2008–09, 37 Enterobacteriaceae isolates 
with the NDM-1 enzyme were referred from 25 laboratories 
across England with single representatives also from 
Scotland and Northern Ireland. These were identiﬁ ed as 
K pneumoniae (21 isolates), E coli (seven), Enterobacter spp 
(ﬁ ve), Citrobacter freundii (two), Morganella morganii (one), 
and Providencia spp (one). They were from 29 patients and 
had been isolated from urine (15 patients), blood (three), 
burn or wound swab (four), sputum (two), central line tip 
(one), throat swab (one), or unknown specimens (three). 
The mean age of the patients was 60 years (SD 24; 
range 1–87), with 17 male patients and 12 female patients. 
At least 17 patients had a history of travelling to India or 
Pakistan within 1 year, and 14 of them had been admitted 
to a hospital in these countries. Reasons for these 
admissions included renal or bone marrow transplantation, 
dialysis, cerebral infarction, chronic obstructive pulmonary 
disease, pregnancy, burns, road traﬃ  c accidents, and 
cosmetic surgery.
Isolates, NDM-1-positive bacteria from Mumbai 
(32 isolates), Varanasi (13), and Guwahati (three) in India, 
and 25 isolates from eight cities in Pakistan (Charsadda, 
Faisalabad, Gujrat, Haﬁ zabad, Karachi, Lahore, Rahim 
Yar Khan, and Sheikhupura) were also analysed in exactly 
the same manner but in laboratories in India and 
Pakistan. These isolates were from a range of infections 
including bacteraemia, ventilator-associated pneumonia, 
and community-acquired urinary tract infections. 
All the isolates producing the NDM-1 enzyme were 
resistant to several antibiotic classes (table). The 37 UK 
isolates were all resistant to imipenem and ertapenem, 
although a single M morganii isolate remained susceptible, 
at least in vitro, to meropenem (MIC 2 mg/L). Only four 
UK isolates remained susceptible to the monobactam 
aztreonam (MICs ≤1 mg/L), which is unaﬀ ected by 
metallo-carbapenemases including NDM-1; the other UK 
isolates were all resistant to all β-lactams, including 
aztreonam, suggesting the concurrent presence of 
additional β-lactamases including ESBLs and AmpC 
enzymes—identiﬁ ed by sequencing as mainly blaCTX-M-15 
and blaCMY-4. All 37 isolates were resistant to amikacin and 
tobramycin, although one isolate was susceptible to 
gentamicin and three to ciproﬂ oxacin. MICs of minocycline 
were consistently 2 mg/L or greater, interpreted as non-
susceptible with the BSAC and European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) 
breakpoints for doxycycline, but most (33 of 37) were 
susceptible to colistin (MICs ≤4 mg/L) and 26 were 
suseptible to tigecycline (MICs ≤1 mg/L; ﬁ gure 2).
The 44 isolates from Chennai were similarly resistant to 
all β-lactam antibiotics, ﬂ uoroquinolones, and 
aminoglycosides, apart from two that were sensitive to 
gentamicin. 39 were resistant to minocycline with MICs 
>2 mg/L, 19 to tigecycline, and three to colistin (table and 
ﬁ gure 2). Two of the three isolates resistant to colistin 
were Proteus spp, which are intrinsically resistant, and the 
third was a K pneumoniae strain (colistin MIC >32 mg/L; 
UK (n=37) Chennai (n=44) Haryana (n=26)
MIC50; MIC90 (mg/L) Proportion 
susceptible*
MIC50; MIC90 (mg/L) Proportion 
susceptible*
MIC50; MIC90 (mg/L) Proportion 
susceptible*
Imipenem 32; 128 0% 64; 128 0% 32; 128 0%
Meropenem 32; 32 3% 32; >32 3% >32; >32 3%
Piperacillin-tazobactam >64; >64 0% >64; >64 0% >64; >64 0%
Cefotaxime >256; >256 0% >256; >256 0% >256; >256 0%
Ceftazidime >256; >256 0% >256; >256 0% >256; >256 0%
Cefpirome >64; >64 0% >64; >64 0% >64; >64 0%
Aztreonam >64; >64 11% >64; >64 0% >64; >64 8%
Ciproﬂ oxacin >8; >8 8% >8; >8 8% >8; >8 8%
Gentamicin >32; >32 3% >32; >32 3% >32; >32 3%
Tobramycin >32; >32 0% >32; >32 0% >32; >32 0%
Amikacin >64; >64 0% >64; >64 0% >64; >64 0%
Minocycline 16; >32 0% 32; >32 0% 8; 16 0%
Tigecycline 1; 4 64% 4; 8 56% 1; 2 67%
Colistin 0·5; 8 89%† 1; 32 94%† 1; 2 100%†
MIC=minimum inhibitory concentration. *Susceptibility deﬁ ned by British Society for Antimicrobial Chemotherapy and European Committee on Antimicrobial Susceptibility 
Testing breakpoints; doxycycline breakpoints were used for minocycline. †Colistin-resistant UK isolates were one isolate of Morganella morganii and one Providencia sp (both 
intrinsically-resistant species), also one Klebsiella pneumoniae and one Enterobacter sp.
Table: Antibiotic susceptibilities for NDM-1-positive Enterobacteriaceae isolated in the UK and north (Chennai) and south India (Haryana)
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tigecycline MIC 8 mg/L). Although several reports from 
Greece have noted K pneumoniae isolates as colistin 
resistant, we believe our isolate is truly pan-resistant.24,25 
Most of the 26 Haryana isolates were resistant to all 
β-lactam and non-β-lactam antibiotics, although three 
were susceptible to aztreonam and one to ciproﬂ oxacin 
and amikacin. Minocycline MICs for the Haryana isolates 
were 8–16 mg/L and ten isolates had intermediate 
resistance (2 mg/L) to tigecycline by EUCAST criteria. 
None were resistant to colistin (table and ﬁ gure 2). 
The 21 Klebsiella isolates from the UK had diﬀ erent 
PFGE proﬁ les and were typed to 19 distinct groups with 
only two related pairs, both of which included isolates 
from epidemiologically linked patients, probably 
representing cases of cross-infection. All the UK E coli 
isolates were diﬀ erent. The Chennai isolates were also 
very diﬀ erent, with none similar to each other. By contrast, 
the 26 NDM-positive K pneumoniae isolates from Haryana 
belonged to a single PFGE proﬁ le suggesting clonal 
spread. We could not prove statistically signiﬁ cant strain 
relatedness between the Indian and UK isolates.
Isolates from Chennai, Haryana, and the UK’s Antibiotic 
Resistance Monitoring and Reference Laboratory were 
analysed for the location of the blaNDM-1 gene by S1 digestion 
of DNA, and then PFGE and direct probing of the gels 
with a radiolabelled blaNDM-1 gene. Each of the three groups 
of isolates typically carried several plasmids, with some 
isolates having up to eight plasmids (ﬁ gure 3). 
Indian isolates had blaNDM-1 exclusively on plasmids. 
Plasmids from the non-clonal Chennai isolates ranged 
from 50 kb to 350 kb, whereas those from the clonal 
K pneumoniae from Haryana were predominately either 
118 kb (54%) or 50 kb (36%). The UK isolates had a more 
diverse range of plasmid sizes, 80 kb to greater than 500 kb. 
Three UK isolates also carried blaNDM-1 on their chromosome, 
suggesting in-situ movement of blaNDM-1. There were many 
plasmids of identical size in isolates collected from India 
and the UK (data not shown), suggesting plasmid 
movement between bacterial isolates. In some isolates, 
blaNDM-1 was carried on more than one plasmid (ﬁ gure 4). 
47 isolates from Chennai (33) and Haryana (14) were 
randomly chosen for further investigation with PCR and 
DNA probing to verify the origin of replication 
(incompatibility type) for plasmids carrying blaNDM-1.11,22 
Plasmids carrying blaNDM-1 from the 14 isolates from 
Haryana could not be typed. 13 of the 33 isolates from 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Figure 3: The diﬀ erence in plasmid numbers from a selection of Indian isolates
Tracks 1–10 show the number of plasmids in isolates from Chennai (south India) 
and tracks 11–18 show the number of plasmids in isolates from Haryana (north 
India). Most isolates contained up to seven plasmids, and in Chennai there was 
greater variation than in isolates from Haryana showing the bacterial clonality of 
NDM-1 carriage in Haryana.
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Figure 2: 90% minimum inhibitory concentration (MIC90) for Enterobacteriaceae from Chennai and Haryana, India, and the UK
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Chennai carried blaNDM-1 on A/C-type plasmids and one 
blaNDM-1 positive plasmid was incompatibility type FI/FII. 
Similarly, when the 32 randomly selected UK isolates 
were assessed with the same methods, 22 carried A/C 
type plasmids. The other blaNDM-1 positive plasmids from 
India and the UK that were A/C and FI/FII negative 
could not be typed.
Transconjugants were created in E coli J53 from the 
33 Chennai and 32 UK isolates; however, the isolates 
from Haryana did not produce transconjugates.22 All 
transconjugants were shown by PCR to contain blaNDM-1.
We compared the sizes of the plasmids in the clinical 
strains with those of the transconjugants and, in about 
10% of cases, the plasmid had altered in size during 
transfer. In most cases the plasmid had lost DNA but two 
of 102 had gained DNA during transfer. 
In addition to the collections of isolates from Chennai 
and Haryana detailed above, we have conﬁ rmed by PCR 
alone the presence of genes encoding NDM-1 in 
carbapenem-resistant Enterobacteriaceae isolated from 
Guwahati, Mumbai, Varanasi, Bangalore, Pune, Kolkata, 
Hyderabad, Port Blair, and Delhi in India, eight cities 
(Charsadda, Faisalabad, Gujrat, Haﬁ zabad, Karachi, 
Lahore, Rahim Yar Khan, and Sheikhupura) in Pakistan, 
and Dhaka in Bangladesh (ﬁ gure 5) suggesting wide-
spread dissemination. 
Discussion
Enterobacteriaceae with NDM-1 carbapenemases are 
highly resistant to many antibiotic classes and 
potentially herald the end of treatment with β-lactams, 
ﬂ uoroquinolones, and aminoglycosides—the main 
antibiotic classes for the treatment of Gram-negative 
infections. Only a few isolates remained sensitive to 
individual aminoglycosides and aztreonam, perhaps 
owing to the loss of resistance genes (eg, those encoding 
aminoglycoside modifying enzymes, 16S rRNA 
methylases, or blaCMY-4).12,22 Most isolates remained 
susceptible to colistin and tigecycline.
Typing did not identify common strain types of E coli or 
K pneumoniae between the Indian subcontinent and the 
UK or between north and south India. Nevertheless, the 
NDM-1-positive K pneumoniae isolates from Haryana 
were clonal, suggesting that some strains could potentially 
cause outbreaks. Most blaNDM-1 positive plasmids were 
readily transferable and prone to rearrangement, losing 
or (more rarely) gaining DNA on transfer. This 
transmissibility and plasticity implies an alarming 
potential to spread and diversify among bacterial 
populations. Curiously, many of the plasmids were 
incompatibility A/C types—a group not commonly 
associated with multidrug-resistant phenotypes. 
Although antibiotic resistance in China has been 
highlighted as a concern,4 the rapid emergence of 
blaNDM-1 deserves equal attention. A recent editorial by 
Abdul Ghafur26 highlights the widespread non-
prescription use of antibiotics in India, leading to huge 
selection pressure, and predicts that the NDM-1 
problem is likely to get substantially worse in the 
foreseeable future. This scenario is of great concern 
because there are few new anti-Gram-negative 
antibiotics in the pharmaceutical pipeline and none 
that are active against NDM-1 producers.20 Even more 
disturbing is that most of the Indian isolates from 
Chennai and Haryana were from community-acquired 
infections, suggesting that blaNDM-1 is widespread in 
the environment.27
The introduction of NDM-1 into the UK is also very 
worrying and has prompted the release of a National 
Resistance Alert 3 notice by the Department of Health on 
the advice of the Health Protection Agency.28 Given the 
historical links between India and the UK, that the UK is 
the ﬁ rst western country to register the widespread 
presence of NDM-1-positive bacteria is unsurprising. 
However, it is not the only country aﬀ ected. In addition 
to the ﬁ rst isolate from Sweden, a NDM-1-positive 
K pneumoniae isolate was recovered from a patient who 
was an Australian resident of Indian origin and had 
visited Punjab in late 2009. The isolate was highly 
1 2 3 4 5 6 7 8 9 10 11Marker 1 2 3 4 5 6 7 8 9 10 11
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Figure 4: Hybridisation results of UK isolates with blaNDM-1
Pulsed-ﬁ eld gel of S1-treated plasmid DNA of UK isolates M15–M27 stained with 
ethidium bromide (A). Molecular weight marker is Lambda concatamer 
50–1000 kb. The chromosome of each isolate is the bright band at the top of 
each lane and bright bands below are plasmids of various sizes. Autoradiogram 
of gel A probed with a blaNDM-1 showing individual or multiple plasmids in each 
strain carrying blaNDM-1 (B).
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Figure 5: Distribution of NDM-1-producing Enterobacteriaceae strains in Bangladesh, Indian, Pakistan, and the UK
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resistant and carried blaNDM-1 on an incompatibility A/C 
type plasmid similar to those in India and the UK.
Several of the UK source patients had undergone 
elective, including cosmetic, surgery while visiting India 
or Pakistan. India also provides cosmetic surgery for other 
Europeans and Americans, and blaNDM-1 will likely spread 
worldwide. It is disturbing, in context, to read calls in the 
popular press for UK patients to opt for corrective surgery 
in India with the aim of saving the NHS money.29 As our 
data show, such a proposal might ultimately cost the NHS 
substantially more than the short-term saving and we 
would strongly advise against such proposals. The 
potential for wider international spread of producers and 
for NDM-1-encoding plasmids to become endemic 
worldwide, are clear and frightening. 
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